AVELUMAB for Transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 554 adverse event reports in the FDA FAERS database where AVELUMAB was used for Transitional cell carcinoma.
Most Reported Side Effects for AVELUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 361 | 9.9% | 361 | 35 |
| Disease progression | 355 | 9.8% | 207 | 65 |
| Off label use | 200 | 5.5% | 56 | 55 |
| Diarrhoea | 153 | 4.2% | 17 | 84 |
| Infusion related reaction | 142 | 3.9% | 14 | 51 |
| Pyrexia | 129 | 3.6% | 18 | 90 |
| Fatigue | 124 | 3.4% | 19 | 36 |
| Neoplasm progression | 119 | 3.3% | 69 | 29 |
| Dyspnoea | 100 | 2.8% | 15 | 66 |
| Nausea | 99 | 2.7% | 15 | 50 |
| Chills | 98 | 2.7% | 6 | 37 |
| Interstitial lung disease | 96 | 2.6% | 19 | 46 |
| Hypertension | 89 | 2.5% | 6 | 35 |
| Rash | 83 | 2.3% | 7 | 24 |
| Acute kidney injury | 82 | 2.3% | 14 | 67 |
Other Indications for AVELUMAB
Product used for unknown indication (439)
Neuroendocrine carcinoma of the skin (401)
Renal cell carcinoma (316)
Metastatic renal cell carcinoma (170)
Bladder cancer (167)
Transitional cell carcinoma metastatic (144)
Non-small cell lung cancer (132)
Bladder transitional cell carcinoma (104)
Neoplasm malignant (90)
Ovarian cancer (84)
Other Drugs Used for Transitional cell carcinoma
PEMBROLIZUMAB (1,951)
ENFORTUMAB VEDOTIN-EJFV (1,179)
GEMCITABINE (825)
ATEZOLIZUMAB (788)
CISPLATIN (672)
ENFORTUMAB VEDOTIN (649)
NIVOLUMAB (595)
CARBOPLATIN (493)
GEMCITABINE\GEMCITABINE (255)
PACLITAXEL (215)